Enliven Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ELVN and other ETFs, options, and stocks.About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.
CEOSamuel S. Kintz
CEOSamuel S. Kintz
Employees62
Employees62
HeadquartersBoulder, Colorado
HeadquartersBoulder, Colorado
Founded2019
Founded2019
Employees62
Employees62
ELVN Key Statistics
Market cap998.22M
Market cap998.22M
Price-Earnings ratio-9.13
Price-Earnings ratio-9.13
Dividend yield—
Dividend yield—
Average volume794.12K
Average volume794.12K
High today$18.81
High today$18.81
Low today$16.62
Low today$16.62
Open price$18.70
Open price$18.70
Volume1.41M
Volume1.41M
52 Week high$25.37
52 Week high$25.37
52 Week low$13.30
52 Week low$13.30
Stock Snapshot
Enliven Therapeutics(ELVN) stock is priced at $16.85, giving the company a market capitalization of 998.22M. It carries a P/E multiple of -9.13.
As of 2025-12-13, Enliven Therapeutics(ELVN) stock has fluctuated between $16.62 and $18.81. The current price stands at $16.85, placing the stock +1.4% above today's low and -10.4% off the high.
Enliven Therapeutics(ELVN) shares are trading with a volume of 1.41M, against a daily average of 794.12K.
In the last year, Enliven Therapeutics(ELVN) shares hit a 52-week high of $25.37 and a 52-week low of $13.30.
In the last year, Enliven Therapeutics(ELVN) shares hit a 52-week high of $25.37 and a 52-week low of $13.30.
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own ELVN. This list is generated using Robinhood data, and it’s not a recommendation.